Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


05.12.2022

1 Am J Pathol
3 Ann Thorac Surg
6 Anticancer Res
7 BMC Cancer
1 Cancer
1 Clin Cancer Res
3 J Clin Endocrinol Metab
1 Nat Rev Cancer
18 Oral Oncol
2 PLoS One
3 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. BLOCKER SJ, Morrison S, Everitt JI, Cook J, et al
    Whole-Slide Cytometric Feature Mapping for Distinguishing Tumor Genomic Subtypes in Head and Neck Squamous Cell Carcinoma Whole-Slide Images.
    Am J Pathol. 2022 Nov 19:S0002-9440(22)00362.
    PubMed         Abstract available


    Ann Thorac Surg

  2. PENDLETON AC, Stenson K, Tabachnick D, Seder CW, et al
    LAPAROSCOPIC TRANSHIATAL ESOPHAGECTOMY WITH EN BLOC POSTERIOR TRACHEAL WALL RESECTION.
    Ann Thorac Surg. 2022 Feb 23. pii: S0003-4975(22)00231.
    PubMed         Abstract available

  3. WILLIAMS E, Bolger JC, Darling G
    Radical Resection in an Era of Immune Therapy for Primary Esophageal Melanoma.
    Ann Thorac Surg. 2022;114:e423-e425.
    PubMed         Abstract available

  4. ZHOU N, Hofstetter WL
    Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers.
    Ann Thorac Surg. 2021 Dec 6. pii: S0003-4975(21)02018.
    PubMed         Abstract available


    Anticancer Res

  5. KUSAKA T, Shiga K, Katagiri K, Saito D, et al
    Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
    Anticancer Res. 2022;42:6047-6056.
    PubMed         Abstract available

  6. INAGAKI T, Sato M, Kin M, Otsuka K, et al
    Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
    Anticancer Res. 2022;42:6071-6081.
    PubMed         Abstract available

  7. HAMAI Y, Emi M, Ibuki Y, Kurokawa T, et al
    Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Anticancer Res. 2022;42:6037-6045.
    PubMed         Abstract available

  8. KOUZU K, Tsujimoto H, Uehata N, Ishibashi Y, et al
    Modified Geriatric Nutrition Risk Index as a Prognostic Predictor for Unresectable/Recurrent Esophageal Cancer.
    Anticancer Res. 2022;42:5999-6006.
    PubMed         Abstract available

  9. MORISHITA Y, Takenouchi K, Sakashita S, Matsuura K, et al
    Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5751-5761.
    PubMed         Abstract available

  10. MOTOYAMA S, Hosaka M, Kamei T, Ueno M, et al
    A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:6105-6112.
    PubMed         Abstract available


    BMC Cancer

  11. LUO X, Huang X, Luo J, Xiao J, et al
    Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial.
    BMC Cancer. 2022;22:1235.
    PubMed         Abstract available

  12. KAO HF, Huang HC, Liao BC, Hong RL, et al
    Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
    BMC Cancer. 2022;22:1228.
    PubMed         Abstract available

  13. YANG XL, Zhang LL, Kou J, Zhou GQ, et al
    Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure.
    BMC Cancer. 2022;22:1230.
    PubMed         Abstract available

  14. DUPONT M, Carlier C, Gower-Rousseau C, Barbier-Lider P, et al
    Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
    BMC Cancer. 2022;22:1219.
    PubMed         Abstract available

  15. CAO Y, Dong H, Li G, Wei H, et al
    Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma.
    BMC Cancer. 2022;22:1209.
    PubMed         Abstract available

  16. WANG J, Wang N, Zheng Z, Che Y, et al
    Exosomal lncRNA HOTAIR induce macrophages to M2 polarization via PI3K/ p-AKT /AKT pathway and promote EMT and metastasis in laryngeal squamous cell carcinoma.
    BMC Cancer. 2022;22:1208.
    PubMed         Abstract available

  17. SPRAVE T, Gkika E, Verma V, Grosu AL, et al
    Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study.
    BMC Cancer. 2022;22:1236.
    PubMed         Abstract available


    Cancer

  18. BROSE MS, Robinson BG, Sherman SI, Jarzab B, et al
    Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34493.
    PubMed         Abstract available


    Clin Cancer Res

  19. AGGARWAL C, Saba NF, Algazi A, Sukari A, et al
    Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Dec 1:CCR-22-1987. doi: 10.1158/1078-0432.CCR-22-1987.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  20. ZHOU H, Wu J, Shi L, Wang Y, et al
    Analysis of delayed surgery and clinical outcomes in intermediate- and high-risk papillary thyroid cancer.
    J Clin Endocrinol Metab. 2022 Sep 3. pii: 6691129. doi: 10.1210.
    PubMed         Abstract available

  21. PALERMO A, Sodo A, Naciu AM, Gioacchino MD, et al
    Clinical use of Raman spectroscopy improves diagnostic accuracy for indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2022 Sep 14. pii: 6697971. doi: 10.1210.
    PubMed         Abstract available

  22. RIVKEES SA
    Approach to the Patient: Management and the Long-Term Consequences of Graves' Disease in Children.
    J Clin Endocrinol Metab. 2022 Oct 3. pii: 6746564. doi: 10.1210.
    PubMed         Abstract available


    Nat Rev Cancer

  23. RUFFIN AT, Li H, Vujanovic L, Zandberg DP, et al
    Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
    Nat Rev Cancer. 2022 Dec 1. doi: 10.1038/s41568-022-00531.
    PubMed         Abstract available


    Oral Oncol

  24. MANZOOR H, Rasheed A, Zeen F, Sarfraz A, et al
    Anti-PD-1 immunotherapy - Pembrolizumab current clinical trials for advanced head and neck cancer: A mapping systematic study.
    Oral Oncol. 2022;136:106266.
    PubMed        

  25. PENG Y, Liu Y, Shen G, Chen Z, et al
    Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning.
    Oral Oncol. 2022;136:106261.
    PubMed         Abstract available

  26. PARK BJ, Mattox AK, Clayburgh D, Patel M, et al
    Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck.
    Oral Oncol. 2022;135:106183.
    PubMed         Abstract available

  27. KHADEMBASCHI D, Jafri M, Praveen P, Parmar S, et al
    Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: A systematic review and pooled analysis.
    Oral Oncol. 2022;135:106133.
    PubMed         Abstract available

  28. SARAVANAN M
    Constitutive activation of activator protein-1 as a cellular switch and its innovative role in the development of molecular targets for tongue squamous cell carcinoma treatment.
    Oral Oncol. 2022;135:106198.
    PubMed        

  29. TAZEEN S, Suri H, Lakshmi R, Subash A, et al
    Swallowing: A delayed milestone post-surgery in tongue cancers.
    Oral Oncol. 2022;135:106238.
    PubMed         Abstract available

  30. TAVERNA F, Alfieri S, Rebecca R, Giulia C, et al
    Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area.
    Oral Oncol. 2022;135:106229.
    PubMed         Abstract available

  31. GAO X, Tian K, Huang L, Chen J, et al
    Introducing the thin and ultrathin submental artery perforator flaps for precise reconstruction following T1-2 oral cavity cancer resection.
    Oral Oncol. 2022;135:106234.
    PubMed         Abstract available

  32. SMITH JD, Bellile EL, Ellsperman SE, Heft-Neal ME, et al
    Prognostic value of CD103(+) tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma.
    Oral Oncol. 2022;135:106226.
    PubMed         Abstract available

  33. GUNAWARDENA DA, Howes D, Fleming S, Clark J, et al
    Reconstruction of a maxillectomy and rhinectomy defect utilising a novel subperiosteal prosthesis and magnet-retained nasal prosthesis: A case report.
    Oral Oncol. 2022;135:106222.
    PubMed        

  34. MISSALE F, Marchi F, Iandelli A, Subramaniam N, et al
    Oncological outcomes of compartmental surgery and wide local excision in oral tongue and floor of the mouth cancer.
    Oral Oncol. 2022;135:106210.
    PubMed         Abstract available

  35. HENDRIKS T, Flukes S
    Unknown primary Merkel cell carcinoma of the head and neck: Favourable outcomes with definitive radiotherapy.
    Oral Oncol. 2022;135:106228.
    PubMed        

  36. TAZEEN S, Lal R, Kp A, Thakur S, et al
    Molecular and hormonal targets for malignant salivary gland tumors.
    Oral Oncol. 2022;135:106225.
    PubMed        

  37. DE KONING KJ, van Es RJJ, Breimer GE, de Bree R, et al
    Response to: Application of ultrasound-guided resections in surgical removal of squamous cell carcinoma of the tongue.
    Oral Oncol. 2022;135:106199.
    PubMed        

  38. TANG KD, Weeramange CE, Vider J, Hartel G, et al
    Potential use of salivary mRNA-based biomarkers to predict oral squamous cell carcinoma.
    Oral Oncol. 2022;135:106215.
    PubMed        

  39. TAPIA M, Manji J, Dhillon K, Kleid S, et al
    The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
    Oral Oncol. 2022;135:106213.
    PubMed         Abstract available

  40. LASSCHE G, van Boxtel W, Aalders TW, van Hooij O, et al
    Development and characterization of patient-derived salivary gland cancer organoid cultures.
    Oral Oncol. 2022;135:106186.
    PubMed         Abstract available

  41. MALI SB
    Epigenetics: Promising journey so far but ways to go in head neck cancer.
    Oral Oncol. 2022;135:106194.
    PubMed         Abstract available


    PLoS One

  42. PANDA S, Sakthivel P, Gurusamy KS, Sharma A, et al
    Treatment options for resectable hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    PLoS One. 2022;17:e0277460.
    PubMed         Abstract available

  43. JOVANOVIC N, Chinnery T, Mattonen SA, Palma DA, et al
    Sarcopenia in head and neck cancer: A scoping review.
    PLoS One. 2022;17:e0278135.
    PubMed         Abstract available


    Radiother Oncol

  44. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    PubMed         Abstract available

  45. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    PubMed         Abstract available

  46. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: